Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beaumont

Showing results (361-370 of 368) with videos related to

Pageof 37
Sort By:
You have reached the last page of results.This site can display upto 368 results.
Archives of Dermatology|February 22, 2012
Measuring the severity of infantile hemangiomas: instrument development and reliabilityAnita N Haggstrom, Jennifer L Beaumont, Jin-She Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|January 17, 2002
Plateletpheresis concentrates produced with the COMTEC cell separator: the French experienceC Coffe, M Benguella, M Domy, et al.
Future Oncology (London, England)|April 2, 2026
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Neurology|March 13, 2013
Cognition assessment using the NIH ToolboxSandra Weintraub, Sureyya S Dikmen, Robert K Heaton, et al.
Journal of Pediatric Urology|February 11, 2022
Randomized trial of prophylactic antibiotics vs. placebo after midshaft-to-distal hypospadias repair: the PROPHY StudyMark A Faasse, Walid A Farhat, Ilina Rosoklija, et al.
American Journal of Hematology|June 23, 2021
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasoneLarysa Sanchez, Xavier Leleu, Jennifer L Beaumont, et al.
Pageof 37

Showing results (361-370 of 368) with videos related to

Sort By:
Pageof 37
You have reached the last page of results.This site can display upto 368 results.
Archives of Dermatology|February 22, 2012
Measuring the severity of infantile hemangiomas: instrument development and reliabilityAnita N Haggstrom, Jennifer L Beaumont, Jin-She Lai, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 12, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With PembrolizumabMatthew I Milowsky, Peter H O'Donnell, Christopher J Hoimes, et al.
Transfusion and Apheresis Science : Official Journal of the World Apheresis Association : Official Journal of the European Society for Haemapheresis|January 17, 2002
Plateletpheresis concentrates produced with the COMTEC cell separator: the French experienceC Coffe, M Benguella, M Domy, et al.
Future Oncology (London, England)|April 2, 2026
How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer compared with platinum-based chemotherapy: a plain language summary of patient-reported outcomes from the EV-302 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
The Lancet. Oncology|May 31, 2025
Enfortumab vedotin plus pembrolizumab versus chemotherapy in patients with previously untreated locally advanced or metastatic urothelial cancer (EV-302): patient-reported outcomes from an open-label, randomised, controlled, phase 3 studyShilpa Gupta, Yohann Loriot, Michiel S Van der Heijden, et al.
Neurology|March 13, 2013
Cognition assessment using the NIH ToolboxSandra Weintraub, Sureyya S Dikmen, Robert K Heaton, et al.
Journal of Pediatric Urology|February 11, 2022
Randomized trial of prophylactic antibiotics vs. placebo after midshaft-to-distal hypospadias repair: the PROPHY StudyMark A Faasse, Walid A Farhat, Ilina Rosoklija, et al.
American Journal of Hematology|June 23, 2021
Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasoneLarysa Sanchez, Xavier Leleu, Jennifer L Beaumont, et al.
Pageof 37